(Total Views: 490)
Posted On: 11/28/2018 8:18:39 PM
Post# of 30066
Buy beaten down assets, de-risk them and sell or partner the programs.
"As these opportunities mature, become further de-risked and gain traction in the market, AMBS will evaluate the return of capital to Amarantus shareholders to drive AMBS's value and reward shareholder loyalty."
While BP waited for AMBS to fail and hoped to steal the assets, Gerald forged on.
Deal one rounding the corner.
Who's to say this company won't be interested in another asset / Sub of AMBS'.
They still have
Cutanogen Corporation - of which a tentative deal had been in place but subsequently cancelled by Gerald.
Interesting timing.
LymPro 2.0 - under their NeuroDx Sub - with Michael T. Ropacki, PhD as Chief Medical Advisor
MANF Therapeutics - anyone who has read about MANF, speaks for itself.
While AMBS continues to complete a Reg. A.
Sub .03 won't be here for long.
The past is just that.
The future will come fast.
Aloha
"As these opportunities mature, become further de-risked and gain traction in the market, AMBS will evaluate the return of capital to Amarantus shareholders to drive AMBS's value and reward shareholder loyalty."
While BP waited for AMBS to fail and hoped to steal the assets, Gerald forged on.
Deal one rounding the corner.
Who's to say this company won't be interested in another asset / Sub of AMBS'.
They still have
Cutanogen Corporation - of which a tentative deal had been in place but subsequently cancelled by Gerald.
Interesting timing.
LymPro 2.0 - under their NeuroDx Sub - with Michael T. Ropacki, PhD as Chief Medical Advisor
MANF Therapeutics - anyone who has read about MANF, speaks for itself.
While AMBS continues to complete a Reg. A.
Sub .03 won't be here for long.
The past is just that.
The future will come fast.
Aloha
(14)
(0)
